Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2651–2654. doi: 10.1128/aac.40.11.2651

Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.

B L Robbins 1, B H Waibel 1, A Fridland 1
PMCID: PMC163594  PMID: 8913483

Abstract

This report describes the development of a potentially clinical method to measure the cellular metabolites of zidovudine (ZDV) in patients receiving the drug. This new method combines the use of Sep-Pak cartridges to separate ZDV phosphates with radioimmunoassaying to quantitate ZDV. The detection limit is 0.02 pmol/10(6) cells, and this assay can measure a wide range of intracellular drug concentrations. The use of the cartridge-radioimmunoassay methodology should prove very useful for in vivo cellular pharmacokinetic studies of ZDV.

Full Text

The Full Text of this article is available as a PDF (175.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boucher F. D., Modlin J. F., Weller S., Ruff A., Mirochnick M., Pelton S., Wilfert C., McKinney R., Jr, Crain M. J., Elkins M. M. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan;122(1):137–144. doi: 10.1016/s0022-3476(05)83507-3. [DOI] [PubMed] [Google Scholar]
  2. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  3. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  4. Fridland A., Connelly M. C., Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol. 1990 May;37(5):665–670. [PubMed] [Google Scholar]
  5. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ingrand D., Weber J., Boucher C. A., Loveday C., Robert C., Hill A., Cammack N. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. AIDS. 1995 Dec;9(12):1323–1329. doi: 10.1097/00002030-199512000-00004. [DOI] [PubMed] [Google Scholar]
  7. Kline M. W., Dunkle L. M., Church J. A., Goldsmith J. C., Harris A. T., Federici M. E., Schultze M. E., Woods L., Loewen D. F., Kaul S. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 1995 Aug;96(2 Pt 1):247–252. [PubMed] [Google Scholar]
  8. Kuster H., Vogt M., Joos B., Nadai V., Lüthy R. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis. 1991 Oct;164(4):773–776. doi: 10.1093/infdis/164.4.773. [DOI] [PubMed] [Google Scholar]
  9. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  10. Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995 Aug 4;269(5224):696–699. doi: 10.1126/science.7542804. [DOI] [PubMed] [Google Scholar]
  11. Meng T. C., Fischl M. A., Richman D. D. AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. Am J Med. 1990 May 21;88(5B):27S–30S. doi: 10.1016/0002-9343(90)90419-e. [DOI] [PubMed] [Google Scholar]
  12. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Murphy R. Clinical aspects of human immunodeficiency virus disease: clinical rationale for treatment. J Infect Dis. 1995 Mar;171 (Suppl 2):S81–S87. doi: 10.1093/infdis/171.supplement_2.s81. [DOI] [PubMed] [Google Scholar]
  14. Robbins B. L., Rodman J., McDonald C., Srinivas R. V., Flynn P. M., Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1994 Jan;38(1):115–121. doi: 10.1128/aac.38.1.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sale M., Sheiner L. B., Volberding P., Blaschke T. F. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther. 1993 Nov;54(5):556–566. doi: 10.1038/clpt.1993.188. [DOI] [PubMed] [Google Scholar]
  16. Skowron G., Bozzette S. A., Lim L., Pettinelli C. B., Schaumburg H. H., Arezzo J., Fischl M. A., Powderly W. G., Gocke D. J., Richman D. D. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med. 1993 Mar 1;118(5):321–330. doi: 10.7326/0003-4819-118-5-199303010-00001. [DOI] [PubMed] [Google Scholar]
  17. Slusher J. T., Kuwahara S. K., Hamzeh F. M., Lewis L. D., Kornhauser D. M., Lietman P. S. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother. 1992 Nov;36(11):2473–2477. doi: 10.1128/aac.36.11.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sommadossi J. P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. J Infect Dis. 1995 Mar;171 (Suppl 2):S88–S92. doi: 10.1093/infdis/171.supplement_2.s88. [DOI] [PubMed] [Google Scholar]
  19. Toyoshima T., Kimura S., Muramatsu S., Takahagi H., Shimada K. A sensitive nonisotopic method for the determination of intracellular azidothymidine 5'-mono-, 5'-di-, and 5'-triphosphate. Anal Biochem. 1991 Aug 1;196(2):302–307. doi: 10.1016/0003-2697(91)90470-e. [DOI] [PubMed] [Google Scholar]
  20. Törnevik Y., Ullman B., Balzarini J., Wahren B., Eriksson S. Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol. 1995 Mar 15;49(6):829–837. doi: 10.1016/0006-2952(94)00453-s. [DOI] [PubMed] [Google Scholar]
  21. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  22. van Leeuwen R., Katlama C., Kitchen V., Boucher C. A., Tubiana R., McBride M., Ingrand D., Weber J., Hill A., McDade H. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995 May;171(5):1166–1171. doi: 10.1093/infdis/171.5.1166. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES